List of sponsors
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. TEGSEDI is approved in the U.S., E.U. and Canada. WAYLIVRA is under regulatory review for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea is available at www.akceatx.com.
Alexion is a global biopharmaceutical company focused on bringing hope to patients and families affected by rare diseases by delivering innovative, life-changing therapies. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and refractory generalized myasthenia gravis (gMG). As the global leader in complement inhibition, Alexion is leveraging its experience in complement biology to pursue novel molecules and targets in the complement cascade. Alexion’s development efforts focus on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS) diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform. Alnylam’s first U.S. FDA-approved RNAi therapeutic is ONPATTRO™ (patisiran) lipid complex injection available in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. In the EU, ONPATTRO is approved for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 1000 people worldwide and is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
AveXis – now a Novartis company – is a clinical-stage gene therapy company focused on developing and commercializing novel treatments for patients and families affected by rare and life threatening neurological genetic diseases. AveXis is dedicated to advancing the science of gene therapy to make a difference in the fight against devastating hereditary diseases.
The goal of AveXis’ cutting-edge science is to stop and prevent further disease progression by replacing a lost or defective gene with a fully-functioning copy of the gene using a one-time delivery method.
Founded in 1924, BIAL's mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide. For more information on BIAL: www.bial.com
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, acute neurology, Alzheimer’s disease and dementia. Biogen also manufactures and commercializes biosimilars of advanced biologics.
To learn more, please visit www.biogen.com.
Created in 1982 by Dr Jeanne-Marie Lecomte and Pr Jean-Charles Schwartz, Bioprojet is a medium size, independent Research and Development pharmaceutical company. Bioprojet’s purpose is to design, select and develop innovative drugs, mostly in the CNS field, acting on novel biological targets discovered in collaboration with basic science institutes like French INSERM.
CeGaT is a leading global provider of genetic diagnostics and sequencing services. The company combines its next-generation sequencing (NGS) process and analysis pipelines with its medical expertise - dedicated to identify the genetic cause of disease and supporting patient management. An interdisciplinary team of scientists and human geneticists evaluates the data and summarizes the findings in a comprehensive medical report. All services are performed in-house. CeGaT, founded in 2009 and based in Tuebingen, Germany, is accredited according to CAP, CLIA and DIN EN ISO 15189:2014.
Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly-owned subsidiary and International Headquarter of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
The company was founded in 1997 and its first product was developing a 32 channel EEG device which was completed and sold in 1998. In the following years additional neurology products have been developed including EMG, PSG and TMS devices. The initial sales were to the Czech Republic but soon thereafter were offered in international markets. Due to the high level of innovation and modern design of the products, Deymed has become an established worldwide leader in neurology for both clinical and research applications.
Therapeutic devices have also been a significant part of the product portfolio including EEG Biofeedback and repetitive magnetic stimulators for depression. Deymed strives to continuously improve on and advance their products in a way that brings new possibilities to its users. High signal quality, ease of use, portability and reliability are the hallmarks of Deymed systems.
The European Pain Federation EFIC is a multidisciplinary professional organisation in the field of pain research and medicine, consisting of the 37 chapters of the International Association for the Study of Pain (IASP®), which are the IASP approved official National Pain Societies in each country. Established in 1993, The European Pain Federation EFIC constituent chapters represent Pain Societies from 37 European countries and close to 20,000 physicians, basic researchers, nurses, physiotherapists, psychologists and other healthcare professionals across Europe, who are involved in pain management and pain research.
Contact: 1000 Brussels, Belgium, Donna Walsh, firstname.lastname@example.org, www.efna.net,
The European Federation of Neurological Associations [EFNA] is an umbrella group representing pan-European neurology patient groups.Our slogan ‘Empowering Patient Neurology Groups’ encapsulates our goals as an Association. We strive to add capacity to our members – allowing them to be the most effective advocates possible in their own disease specific areas.EFNA embraces the concept of Partnership for Progress – working at a high level with relevant stakeholders from the fields of policy, medical, scientific/research, industry, patient partners and other key opinion leaders.
The European Federation of NeuroRehabilitation Societies (EFNR) and the World Federation for NeuroRehabilitation (WFNR) are multidisciplinary organizations open to any professional with an interest in neurological rehabilitation. The organizations exist to act as a forum of communication between those with an interest in the subject and are dedicated to research, education, intellectual and scientific exchange, advocacy and philanthropic activities in the field of neurorehabilitation medicine.
The EHDN is a nonprofit research network committed to advancing research, facilitating the conduct of clinical trials, and improving clinical care in HD. Through the EHDN a platform has been created such that basic scientists, clinicians, patients and families can collaborate on academic and industry studies to fulfil its mission. The EHDN is supported by and collaborates closely with CHDI Foundation, Inc.
As a network of stakeholders in HD, the EHDN offers its members the opportunity to take a lead and propose, conduct and publish studies. Anyone who has an interest in HD, including those affected directly by the disease, may join the EHDN and, in so doing, make a personal contribution to HD events and research.
Contact: 1214 Vernier-Geneve, Switzerland, www.lilly.com
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
EpiCARE brings together 28 highly specialized health centres in 13 European countries with expertise in rare and complex epilepsies. EpiCARE offers a coordinated approach for epilepsy diagnostics and treatment by utilizing e-tools and cross-country e-consultancy, thus providing patients with the best expertise available.
NMDs (neuromuscular disorders) collectively affect an estimated 500,000 EU citizens and result in significant costs for families and the healthcare system.
EURO-NMD is a network of 61 of Europe’s leading NMD clinical and research centres in 14 Member States and includes highly active patient organizations. More than 100,000 NMD patients are seen annually by the ERN.
The network addresses harmonizing and implementing standards for clinical and diagnostic best practice, improving equity of care provision across Member States, decreasing time to diagnosis, increasing cost efficiency through better care pathways, access to specialist training and education, application of eHealth services, development and application of care guidelines, facilitating translational and clinical research, harmonising data and samples for research reuse, and sharing of high-quality data. For more info, please contact Ms Heike PASCAL at: email@example.com
The European Reference Network for Rare Neurological Diseases (ERN-RND) is a virtual network of European hospitals with specific and well-known expertise in rare neurological diseases (RNDs). The main objective of the network is to support around 500,000 people in Europe affected by an RND in getting a timely and accurate diagnosis as well as receiving the best treatment and care.
Contact: 4866 Unterach, Austria, Nadja Graf, +43766520555606, firstname.lastname@example.org, www.everpharma.com
We are a globally successful pharmaceutical specialist. At our headquarters in Unterach, Austria, we are always on the search for new therapeutic solutions aimed at improving both the patients’ well-being and quality of life.
Cerebrolysin® is a biotechnologically manufactured original neuropeptide solution that stimulates neurotrophic regulation in the central nervous system. It is indicated for the treatment of stroke, traumatic brain injuries and cognitive impairment/dementia.
Tachyben is used for intravenous treatment of hypertensive emergencies. It is used to control lowering of blood pressure in hypertensive patients during and/or after surgery in cases of severe forms of hypertensive disease.
Among other agents, our product portfolio is strengthened with Dacepton®/Dopaceptin® (apomorphine hydrochloride) for the treatment of disabling motor symptoms in the advanced stage of Parkinson´s disease. We focus on the complete Package of Care including D-mine® Medical Devices for the intermittent and continuous drug delivery.
Recognizing current trends, we keep to our endeavor for further and constant improvement of our patient-oriented services.
Contact: 4521 Schiedberg, Austria, Alexander Lechner, 7251-222-40, email@example.com
g.tec medical engineering GmbH developed the first commercially available Brain-Computer Interface (BCI) system in 1999 and now sells this kind of technology worldwide. BCI systems are mainly used in the research sector, but g.tec develops also applications for the clinical market. One system, called recoveriX, is the first rehabilitation system for stroke patients that pairs mental activities with motor functions. The other system is called mindBEAGLE, which uses BCI technology for quick and easy assessment of Disorder of Consciousness (DOC) patients and even provides basic communication with some of them.
Contact: 4070 Basel, Switzerland, +41616881111, firstname.lastname@example.org, www.roche.com ,
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Contact: 3012 Leuven, Belgium, Wim Van Hecke, 0032 16 369 000, email@example.com, www.icometrix.com
Icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with multiple sclerosis, brain trauma, epilepsy, Alzheimer’s disease, dementia, etc. The fully automated icobrain software is FDA cleared and has market clearance in the USA, Europe, Japan, Canada, Brazil, and Australia. Today, icometrix is internationally active, and the icobrain software is used in 100+ hospitals and icometrix works with some of the largest healthcare providers and pharmaceutical companies on the evaluation of trials of novel drugs for neurological diseases.
Contact: 75015 Paris, France, Jean-Louis Benezeth, +33 1 43 20 16 40 , firstname.lastname@example.org
Impeto Medical is an innovative French company created in 2005, which develops and markets in more than 35 countries SUDOSCAN, a novel medical device allowing the detection and follow-up of autonomic peripheral neuropathy (small fiber neuropathy). SUDOSCAN is a quick diagnostic test (three minutes only), non-invasive, quantitative and objective. This patented technology assesses the sweat glands function by applying a low voltage on feet and hands, reflecting thereby the autonomic small fibers state that innervate sweat glands. More than 100 scientific publications in peer reviewed journals have demonstrated the reliability and benefits of SUDOSCAN in neurology, diabetology, chemo-induced neuropathies and other serious pathologies like hereditary amyloidosis. SUDOSCAN is also included in several international therapeutic guidelines. For more information, visit our website : https://www.impeto-medical.com/
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs nearly 4,000 employees. LivaNova operates as two business franchises: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.A.), respectively. For more information, please visit www.livanova.com.
MedDay is an international, pioneering, biopharmaceutical company developing new drugs that target brain metabolism to treat diseases of the nervous system in areas of high unmet medical need.
At the biopharma business of Merck, we have a long history of focusing on the needs of our customers and patients and we are constantly seeking innovative solutions to advance the state of care in the area of multiple sclerosis (MS). We are committed to developing new treatment options and devices, as well as enhanced patient support services for people living with a neurological disease. Our MS product portfolio includes two complementary products, Rebif® (interferon beta-1a) for relapsing forms of multiple sclerosis (MS), and MAVENCLAD® (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis (RMS). For further details please visit: www.merckneurology.com
Mitsubishi Tanabe Pharma is a global, research-driven pharmaceutical manufacturer which today ranks among the top 50 pharmaceutical companies in the world.
With around 7,200 highly qualified employees, we work on the development and distribution of new active ingredients and pharmaceuticals.
Our advanced drugs save lives and help patients achieve a better quality of life.
Contact: 53562 WI, United States of America, Filomena Goncalves, +1 608-829-8500, email@example.com, www.natus.com
Natus Medical Incorporated
Solutions that span the spectrum of neuro care. Natus is global market leader that provides diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery.
Natus delivers clinician-led solutions that improve outcomes and enhance care for neuro patients through leading-edge equipment, service, education and supplies. Healthcare solutions with one thing in mind. You.
Novartis is a leading global medicines company that is reimagining medicine to improve and extend people’s lives, using innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com.
Contact: 90230 Oulu, Finland, Anne Lämsä, +358 20 741 3380, firstname.lastname@example.org,
Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. Optomed’s customers consist of international health care organisations, hospitals and leading global medical technology companies and distributors. Our camera products have medical approvals in all key markets, including CE (Europe) and FDA (USA), and CFDA (China) for Smartscope PRO.
Contact: NY 10017 New York, USA, +1 212-733-2323, info@Pfizer.com, www.pfizer.com
Pfizer Inc.: Breakthroughs that change patients’ lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. Pharnext identifies and develops synergic combinations of drugs called PLEODRUG™. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team.
Contact: Dublin, Ireland, Sarah Bourgeois, +41 41 743 47 75, sbourgeois(at)ptcbio.com
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
Contact: 01821 Billerica, United States of America, Marisa Kradjian, email@example.com, www.quanterix.com Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Simoa is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Connect with Sunovion at www.sunovion.com
Contact: 1019GM Amsterdam, Netherlands, Job den Hollander, Job.Den.Hollander@Tevaeu.com, www.tevapharm.com
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 43,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With around 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Veriton Pharma Ltd, is a privately owned, speciality pharmaceutical company, dedicated to the development and distribution of high quality, tailored therapy options for people with special medical needs.
Built on the company’s deep expertise in the field of neurology, mainly epilepsy, the company has been awarded its first product licence: Epistatus® 10 mg Oromucosal Solution, Midazolam.
With a personalised service and dedication to meeting customers’ needs, Veriton Pharma is seen as the trusted partner of choice by hospitals and prescribers around the world.
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Contact: 19103 Philadelphia, United States of America, Joey-Rose Jester, firstname.lastname@example.org, email@example.com, https://shop.lww.com
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers, students, and the next generation of healthcare providers. With a focus on clinical effectiveness, research and learning, safety and surveillance, and interoperability and data intelligence, our proven solutions drive effect decision-making and consistent outcomes across the continuum of care.
Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, its goal is to improve people’s health through the development of innovative and quality healthcare solutions.
Zambon products are commercialized in 87 countries. The company has 20 subsidiaries in three different continents – Europe, America and Asia – and owns manufacturing units in Italy, Switzerland, China and Brazil.
The company today has a strong focus on the treatment of rare diseases and specialties, on top of respiratory, pain management and women’s care. Zambon was established in 1906 in Italy and today counts 2,500 employees all over the world. For further information, please visit www.zambon.com
We are a wholesaler company of LED medical devices that are FDA approved not only for skin rejuvenation but also for the Pain Management.
LED- light is known to stimulate the hemoglobin to relieve nitric oxide which promotes blood circulation. It works as vessel dilator. We are a leading company and one of the biggest whole-sellers for LED medical devices (Please click here to view attached trademark). We provide a unique FDA approved medical device called PERFECTIO.
PERFECTIO and other devices are based on NASA science and used for facial and body therapy treatments for different skin problems and illnesses.